Blood Pressure Targets Relevant for Children, Teens

Share this content:
Blood Pressure Targets Relevant for Children, Teens
Blood Pressure Targets Relevant for Children, Teens

TUESDAY, March 29, 2016 (HealthDay News) -- Prehypertension and hypertension in children and adolescents are associated with cardiovascular target organ damage and set the trajectory for early adulthood high blood pressure (BP), according to an editorial published online March 28 in Hypertension.

Bonita Falkner, M.D., from Thomas Jefferson University in Philadelphia, and Samuel S. Gidding, M.D., from Nemours/Alfred I. duPont Hospital for Children in Wilmington, Del., discuss whether the Systolic Blood Pressure Intervention Trial (SPRINT) blood pressure treatment target of less than 120/80 mm Hg is relevant for children.

The researchers note that a BP level of 120/80 mm Hg in adolescence may be associated with early cardiovascular target organ damage. Furthermore, trajectory data indicate that childhood BP levels correlate with BP status in young adulthood, with the hypertensive trajectory in adults having the highest BP levels in childhood and adults with normal and high-normal BP at age 38 years having systolic BP below 120 mm Hg throughout childhood. Primordial prevention, or interventions to prevent development of prehypertension/hypertension in childhood, should focus on conserving normal BP, which for adolescents is less than 120/80 mm Hg. For children younger than 12 years, below 110/70 mm Hg is likely optimal.

"If the SPRINT target of 120/80 mm Hg could be achieved in all those at 18 years of age and maintained for decades, the only SPRINT inclusion criteria that would still be relevant might be age >75 years," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths